{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-01",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "",
      "state": "N/A",
      "country": "",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "67870",
      "recalling_firm": "Pfizer Inc.",
      "address_1": "N/A",
      "address_2": "N/A",
      "postal_code": "N/A",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "US Nationwide including Puerto Rico and US Virgin Islands. 65 federal government accounts received the affected product directly from Pfizer Inc",
      "recall_number": "D-1253-2014",
      "product_description": "Tikosyn¿  (dofetilide) 500 mcg (0.5mg) capsules, 60-count bottle, Rx only Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, NDC 00069-5820-60",
      "product_quantity": "23,064 bottles",
      "reason_for_recall": "Presence of Foriegn Tablets/Capsules: A single Tikosyn¿ (dofetilide) 250 mcg capsule was discovered in one bottle of Tikosyn¿ (dofetilide) 500 mcg (0.5 mg).",
      "recall_initiation_date": "20140408",
      "center_classification_date": "20140422",
      "termination_date": "20170424",
      "report_date": "20140430",
      "code_info": "H48496, H48497; Exp 05/15",
      "more_code_info": ""
    }
  ]
}